Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328225 | 0.81 | MMP13 (0.60) | MMP13SCN9A | |
| SCHEMBL6204333 | 0.81 | MMP13 (0.48) | MMP13SCN9A | |
| SCHEMBL6326034 | 0.80 | KDM4E (0.46) | MMP13L3MBTL1SCN9A | |
| SCHEMBL6328134 | 0.79 | MMP13 (0.46) | MMP13MAPTHTTSCN9A | |
| SCHEMBL6327815 | 0.79 | MMP13 (0.52) | MMP13EGLN1 | |
| SCHEMBL6211896 | 0.74 | MMP13 (0.41) | MMP13SCN9A | |
| SCHEMBL30392173 | 0.72 | KDM4E (0.52) | L3MBTL1NAMPTMAPTNPSR1MEN1 | |
| SCHEMBL6202020 | 0.72 | MMP13 (0.69) | MMP13MAPTSCN9A | |
| SCHEMBL6333055 | 0.72 | MMP13 (0.67) | MMP13 | |
| SCHEMBL6210890 | 0.71 | MMP13 (0.47) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | NOE MARK C (US) | 2005-07-21 | — | — | US | disclosed |
| US-6841671-B2 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1332146-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002034753-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | MMP13 39/4885L3MBTL1 4474/4885NAMPT 165/4885 |
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP8 | MMP13 34/4885L3MBTL1 4500/4885NAMPT 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.